Miniello VL, 2010 Italy
To study if oral intake of L. reuteri could modify the cytokine production in the lung in 4-10 year old children with atopic dermatitis (AD) and non-allergic dermatitis.
R, DB, PC 8 weeks
L. reuteri: 26 (1×108 CFU) Placebo: 25
• In AD patients only L. reuteri significantly increased the IFN-gamma production and decreased IL-4 levels in ex haled breath condensate. The Th2/Th1 cytokines quotient was thereby modified in a positive way.
• No changes in clinical scores of eczema
Miraglia del Giudice M, 2012 Italy
The effect of L. reuteri in children 6-14y with well-controlled asthma, on airway inflamma tion as measured by certain inflammatory parametaers, and clinically.
R, DB, PC 60 days
L. reuteri: 22 (1×108 CFU) Placebo: 21
Compared to placebo L. reuteri significantly reduced airway inflammation, shown as changed levels in exhaled breath condensate:
• reduction of exhaled nitric oxide (FeNO)
• reduction of the cytokine IL-2
• increase of the cytokine IL-10 Clinical parameters, FEV1 and children’s asthma control test (C-ACT), did not differ within or between groups during the treatment.
Miraglia del Giudice M, 2016 Italy
To test the effects of L. reuteri DSM 17938 in combination with vitamin D, on airway inflamma tion in vit. D-deficient children (6 14y) with well-controlled asthma, and allergy to house dust mite. Primary outcome was bronchial inflammation and secondary outcomes were asthma control measured by questionnaire (Childhood Asthma Control Test [C-ACT]), and lung function evaluated by spirometry.
R, DB, PC 90 days + follow-up after another 30 days
L. reuteri: 14 (1×108 CFU + vit D. 400 IU/ 10µg) Placebo: 15
Compared to placebo, L. reuteri + vit. D significantly:
• Reduced bronchial inflammation assessed by fractional exhaled nitric oxide
• the effect was sustained during the follow-up month In addition, there was a reduced response to bronchodila tion in actively-treated children. These findings were asso ciated with significant increase in serum vit. D3 concentra tion in the active group.
Gromert N, 2009 (abstract) Sweden
Study on L. reuteri as an adjunct to standard treatment of atopic eczema in 3 months–4 year old children.
R, DB, PC 12 months
L. reuteri: 25 (1×108 CFU) Placebo: 25
L. reuteri significantly reduced:
• Extension of the eczema
• Itching and loss of sleep
• Skin prick test reaction to peanut allergen Total IgE at 12 months was at steady state, while it was significantly increased in the placebo group
Cirillo AI, 2005 (abstract) Italy
To reduce risk of worsening of atopic eczema during period with cow’s milk intake, in 3–5 year old children.
Open 3 months
L. reuteri: 8 (2×108 CFU) Control: 7
• Atopic eczema relief in all children on L. reuteri
• Control: all children got worse in their eczema